Aldose reductase (AR) is a multifunctional enzyme that catalyzes the reduction of glucose and lipid peroxidation-derived aldehydes. During myocardial ischemia, the activity of AR is increased due to the oxidation of its cysteine residues to sulfenic acids. It is not known, however, whether the activated, sulfenic form of the protein (AR-SOH) is converted back to its reduced, unactivated state (AR-SH). We report here that in perfused mouse hearts activation of AR during 15 min of global ischemia is completely reversed by 30 min of reperfusion. During reperfusion, AR-SOH was converted to a mixed disulfide (AR-SSG). Deactivation of AR and the appearance of AR-SSG during reperfusion were delayed in hearts of mice lacking glutathione S-transferase P (GSTP). In vitro, GSTP accelerated glutathiolation and inactivation of AR-SOH. Reduction of AR-SSG to AR-SH was facilitated by glutaredoxin (GRX). Ischemic activation of AR was increased in GRX-null hearts but was attenuated in the hearts of cardiospecific GRX transgenic mice. Incubation of AR-SSG with GRX led to the regeneration of the reduced form of the enzyme. In ischemic cardiospecific AR transgenic hearts, AR was co-immunoprecipitated with GSTP, whereas in reperfused hearts, the association of AR with GRX was increased. These findings suggest that upon reperfusion of the ischemic heart AR-SOH is converted to AR-SSG via GSTP-assisted glutathiolation. AR-SSG is then reduced by GRX to AR-SH. Sequential catalysis by GSTP and GRX may be a general redox switching mechanism that regulates the reduction of protein sulfenic acids to cysteines.Myocardial ischemia-reperfusion results in the induction of oxidative stress. Ischemia increases the generation of free radicals and reactive oxygen species (ROS), 2 and the generation of these species is increased further upon reperfusion. In several, but not all, models of ischemia-reperfusion injury, redox changes correlate with functional impairment (1-6). The role of free radicals in inducing myocardial injury was supported by early studies showing that treatment with enzymatic and nonenzymatic antioxidants decreased ischemia-reperfusion injury; however, results with exogenous chemicals or enzymatic antioxidants have not been universally positive. In contrast, newer molecular studies with transgenic and gene-deleted animals provide more rigorous and compelling evidence that oxidative stress is a significant component of ischemia-reperfusion injury. Nonetheless, the mechanisms by which ROS induce ischemia-reperfusion injury remain poorly understood.Although in earlier studies it was assumed that an increase in ROS generation is universally detrimental, more recent work shows that in contrast to their injurious effects at high concentrations ROS at low concentrations can stimulate signaling pathways. Some of these signal transduction events stimulate adaptation and increase tissue resistance to oxidative stress. For instance, it has been shown that brief bouts of ischemia that trigger myocardial preconditioning generate oxidative str...